Literature DB >> 18086758

Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.

Jonathan Beesley1, Susan J Jordan, Amanda B Spurdle, Honglin Song, Susan J Ramus, Suzanne Kruger Kjaer, Estrid Hogdall, Richard A DiCioccio, Valerie McGuire, Alice S Whittemore, Simon A Gayther, Paul D P Pharoah, Penelope M Webb, Georgia Chenevix-Trench.   

Abstract

Although some high-risk ovarian cancer genes have been identified, it is likely that common low penetrance alleles exist that confer some increase in ovarian cancer risk. We have genotyped nine putative functional single-nucleotide polymorphisms (SNP) in genes involved in steroid hormone synthesis (SRD5A2, CYP19A1, HSB17B1, and HSD17B4) and DNA repair (XRCC2, XRCC3, BRCA2, and RAD52) using two Australian ovarian cancer case-control studies, comprising a total of 1,466 cases and 1,821 controls of Caucasian origin. Genotype frequencies in cases and controls were compared using logistic regression. The only SNP we found to be associated with ovarian cancer risk in both of these two studies was SRD5A2 V89L (rs523349), which showed a significant trend of increasing risk per rare allele (P = 0.00002). We then genotyped another SNP in this gene (rs632148; r(2) = 0.945 with V89L) in an attempt to validate this finding in an independent set of 1,479 cases and 2,452 controls from United Kingdom, United States, and Denmark. There was no association between rs632148 and ovarian cancer risk in the validation samples, and overall, there was no significant heterogeneity between the results of the five studies. Further analyses of SNPs in this gene are therefore warranted to determine whether SRD5A2 plays a role in ovarian cancer predisposition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086758      PMCID: PMC2666187          DOI: 10.1158/1055-9965.EPI-07-0542

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  44 in total

1.  Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.

Authors:  Celeste L Pearce; Nick M Makridakis; Ronald K Ross; Malcolm C Pike; Laurence N Kolonel; Brian E Henderson; Juergen K V Reichardt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-04       Impact factor: 4.254

2.  SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.

Authors:  Christos Ntais; Anastasia Polycarpou; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-07       Impact factor: 4.254

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk.

Authors:  Annika Auranen; Amanda B Spurdle; Xiaoqing Chen; Julian Lipscombe; David M Purdie; John L Hopper; Adele Green; Catherine S Healey; Karen Redman; Alison M Dunning; Paul D Pharoah; Douglas F Easton; Bruce A J Ponder; Georgia Chenevix-Trench; Karen L Novik
Journal:  Int J Cancer       Date:  2003-01-20       Impact factor: 7.396

5.  Incessant ovulation--a factor in ovarian neoplasia?

Authors:  M F Fathalla
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

6.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.

Authors:  Tomas Riman; Paul W Dickman; Staffan Nilsson; Nestor Correia; Hans Nordlinder; Cecilia M Magnusson; Elisabete Weiderpass; Ingemar R Persson
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

7.  Polymorphisms associated with circulating sex hormone levels in postmenopausal women.

Authors:  Alison M Dunning; Mitch Dowsett; Catherine S Healey; Louise Tee; Robert N Luben; Elizabeth Folkerd; Karen L Novik; Livia Kelemen; Saeko Ogata; Paul D P Pharoah; Douglas F Easton; N E Day; Bruce A J Ponder
Journal:  J Natl Cancer Inst       Date:  2004-06-16       Impact factor: 13.506

8.  Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay.

Authors:  A Mannermaa; H Peltoketo; R Winqvist; B A Ponder; H Kiviniemi; D F Easton; M Poutanen; V Isomaa; R Vihko
Journal:  Hum Genet       Date:  1994-03       Impact factor: 4.132

Review 9.  Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy.

Authors:  B J Slotman; B R Rao
Journal:  Anticancer Res       Date:  1988 May-Jun       Impact factor: 2.480

10.  Estrogen replacement therapy and ovarian cancer.

Authors:  Aaron R Folsom; Jeffrey P Anderson; Julie A Ross
Journal:  Epidemiology       Date:  2004-01       Impact factor: 4.822

View more
  33 in total

1.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Authors:  Celeste Leigh Pearce; Jennifer A Doherty; David J Van Den Berg; Kirsten Moysich; Chris Hsu; Kara L Cushing-Haugen; David V Conti; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Honglin Song; Susanne K Kjaer; Estrid Hogdall; Claus Hogdall; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Jacek Gronwald; Krzysztof Medrek; Anna Jakubowska; Jan Lubinski; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Christopher K Edlund; Daniel O Stram; Malcolm C Pike; Roberta B Ness; Mary Anne Rossing; Anna H Wu
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

2.  The effect of RAD51 135 G>C and XRCC2 G>A (rs3218536) polymorphisms on ovarian cancer risk among Caucasians: a meta-analysis.

Authors:  Shujing Shi; Lingyan Qin; Mengqiu Tian; Mao Xie; Xiaoxue Li; Chenglin Qi; Xiang Yi
Journal:  Tumour Biol       Date:  2014-03-06

3.  The Arg188His polymorphism in the XRCC2 gene and the risk of cancer.

Authors:  Yonggang Zhang; Haichuan Wang; Yuanling Peng; Yuqi Liu; Tianyuan Xiong; Pei Xue; Liang Du
Journal:  Tumour Biol       Date:  2014-01-12

4.  Polymorphisms in genes hydroxysteroid-dehydrogenase-17b type 2 and type 4 and endometrial cancer risk.

Authors:  Stalo Karageorgi; Monica McGrath; I-Min Lee; Julie Buring; Peter Kraft; Immaculata De Vivo
Journal:  Gynecol Oncol       Date:  2010-12-03       Impact factor: 5.482

5.  Microarray expression profiling of long non-coding RNAs in epithelial ovarian cancer.

Authors:  Ye Ding; Da-Zheng Yang; Yong-Ning Zhai; Kai Xue; Feng Xu; Xiao-Yan Gu; Su-Min Wang
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

6.  Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.

Authors:  Joellen M Schildkraut; Edwin S Iversen; Melanie A Wilson; Merlise A Clyde; Patricia G Moorman; Rachel T Palmieri; Regina Whitaker; Rex C Bentley; Jeffrey R Marks; Andrew Berchuck
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

7.  Genetic variants in XRCC2: new insights into colorectal cancer tumorigenesis.

Authors:  Karen Curtin; Wei-Yu Lin; Rina George; Mark Katory; Jennifer Shorto; Lisa A Cannon-Albright; Gillian Smith; D Timothy Bishop; Angela Cox; Nicola J Camp
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08-18       Impact factor: 4.254

Review 8.  Role of genetic polymorphisms and ovarian cancer susceptibility.

Authors:  Peter A Fasching; Simon Gayther; Leigh Pearce; Joellen M Schildkraut; Ellen Goode; Falk Thiel; Georgia Chenevix-Trench; Jenny Chang-Claude; Shan Wang-Gohrke; Susan Ramus; Paul Pharoah; Andrew Berchuck
Journal:  Mol Oncol       Date:  2009-02-04       Impact factor: 6.603

9.  Consortium analysis of 7 candidate SNPs for ovarian cancer.

Authors:  Susan J Ramus; Robert A Vierkant; Sharon E Johnatty; Malcolm C Pike; David J Van Den Berg; Anna H Wu; Celeste Leigh Pearce; Usha Menon; Aleksandra Gentry-Maharaj; Simon A Gayther; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Honglin Song; Douglas F Easton; Paul D P Pharoah; Montserrat Garcia-Closas; Stephen Chanock; Jolanta Lissowska; Louise Brinton; Kathryn L Terry; Daniel W Cramer; Shelley S Tworoger; Susan E Hankinson; Andrew Berchuck; Patricia G Moorman; Joellen M Schildkraut; Julie M Cunningham; Mark Liebow; Susanne Krüger Kjaer; Estrid Hogdall; Claus Hogdall; Jan Blaakaer; Roberta B Ness; Kirsten B Moysich; Robert P Edwards; Michael E Carney; Galina Lurie; Marc T Goodman; Shan Wang-Gohrke; Silke Kropp; Jenny Chang-Claude; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Ellen L Goode
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

10.  Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.

Authors:  J M Cunningham; R A Vierkant; T A Sellers; C Phelan; D N Rider; M Liebow; J Schildkraut; A Berchuck; F J Couch; X Wang; B L Fridley; A Gentry-Maharaj; U Menon; E Hogdall; S Kjaer; A Whittemore; R DiCioccio; H Song; S A Gayther; S J Ramus; P D P Pharaoh; E L Goode
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.